PHI’s CEO and founder Peter Egelberg comments the latest research results by the scientists at the PHI/UCSF Holographic Imaging Cytometry Center of Excellence.
Utilizing precision genetic engineering and PHI’s HoloMonitor technology, scientists at University of California, San Francisco, have for the first time been able to monitor and map how mutations break down the genetic protection against skin cancer.
Using nanoparticles and HoloMonitor technology Prof. Anette Gjörloff Wingren and her team aim to develop an early screening method that detects cancer by a simple blood test.
In this first version of App Suite three common analyzes are included: cell proliferation, cell motility, and cell quality control. App Suite will be rapidly expanded with additional applications. HoloMonitor® App Suite 2.0 is scheduled to be released to customers in Q4 2018.
Phase Holographic Imaging (PHI) and BioSpherix recently signed a collaboration agreement aiming to co-market the companies’ complementary product lines. BioSpherix, NY USA, manufactures and markets advanced cell incubators.
Interview with CEO Peter Egelberg (Swedish) on biostock.se where he talks about PHI’s progress, where PHI is right now and where PHI wants to be in the near future. “Our goal is to be top of mind when researchers and scientists worldwide are looking for a new cell analytic tool”. You find the interview here.
In the CEO commentary “Redefining aging with HoloMonitor” Peter Egelberg comments on the promising research results that were recently reported by Australian television.
The Nordic Microscopy Society meeting in Lyngby Denmark offers several opportunities to meet with us and to hear about the latest HoloMonitor news.
Decision on rights issue for continued growth, establishment of sales organization and commercial break-through
The Board of directors of Phase Holographic Imaging PHI AB (publ) (”PHI”) has decided to conduct a rights issue of units, which is subject to approval on Extraordinary General Meeting, that can provide the company a total of SEK 64.6 million at the most prior to issuing costs.
PHI hereby announces that net sales during the fourth and final fiscal quarter of 2017/18 amounted to 2.2 (1.2) MSEK, resulting in that the company saleswise achieves its best quarter ever for the second consecutive quarter.